Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 12,500 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $32.37, for a total value of $404,625.00. Following the sale, the chief executive officer now directly owns 441,417 shares in the […]
HC Wainwright reaffirmed their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Friday morning, Benzinga reports. The brokerage currently has a $49.00 target price on the biopharmaceutical company’s stock. CYTK has been the subject of a number of other research reports. UBS Group upped their price objective on […]
Morgan Stanley reiterated their overweight rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $60.00 price target on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the company. JPMorgan Chase & Co. upped their target price on Cytokinetics […]
Cytokinetics (NASDAQ:CYTK – Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11), Briefing.com reports. Cytokinetics had a negative net margin of 439.05% and a negative return on equity of 1,401.63%. The business had revenue of $0.87 million for […]
Cytokinetics (NASDAQ:CYTK – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11), Briefing.com reports. Cytokinetics had a negative return on equity of 1,401.63% and a negative net margin of 5,419.17%. The company had revenue of $0.87 million […]